

Contents

Leading articles

Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy **1**
Stephan Ludwig

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable **5**
Kay Seden, David Back and Saye Khoo

Review

Nasal decolonization of *Staphylococcus aureus* with mupirocin: strengths, weaknesses and future prospects **9**
T. Coates, R. Bax and A. Coates

Systematic review

Antibiotics versus placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials **16**
Evriddiki K. Vouloumanou, Drosos E. Karageorgopoulos, Maria S. Kazantzi, Anastasios M. Kapaskelis and Matthew E. Falagas

Original research

Evolution of raltegravir resistance during therapy **25**
Nadine Sichtig, Saleta Sierra, Rolf Kaiser, Martin Däumer, Stefan Reuter, Eugen Schülter, Andre Altmann, Gerd Fätkenheuer, Ulf Dittmer, Herbert Pfister and Stefan Esser

Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37°C and high humidity **33**
J. Gerardo García-Lerma, Amanda McNulty, Cheryl Jennings, Diana Huang, Walid Heneine and James W. Bremer

Development of homogeneous expression of resistance in methicillin-resistant *Staphylococcus aureus* clinical strains is functionally associated with a β -lactam-mediated SOS response **37**
Arabela Cuirolo, Konrad Plata and Adriana E. Rosato

Increased prevalence and clonal dissemination of multidrug-resistant *Pseudomonas aeruginosa* with the *bla*_{IMP-1} gene cassette in Hiroshima **46**
Syuntaro Kouda, Masaru Ohara, Makoto Onodera, Yoshihiro Fujiue, Megumi Sasaki, Tadahiro Kohara, Seiya Kashiwama, Shizue Hayashida, Toshie Harino, Takahiro Tsuji, Hideyuki Itaha, Naomasa Gotoh, Akio Matsubara, Tsuguru Usui and Motoyuki Sugai

Increased macrolide resistance of *Mycoplasma pneumoniae* in France directly detected in clinical specimens by real-time PCR and melting curve analysis **52**
O. Peuchant, A. Ménard, H. Renaudin, M. Morozumi, K. Ubukata, C. M. Bébéar and S. Pereyre

The inability of a bacteriophage to infect *Staphylococcus aureus* does not prevent it from specifically delivering a photosensitizer to the bacterium enabling its lethal photosensitization **59**
C. K. Hope, S. Packer, M. Wilson and S. P. Nair

A competition-based assay for the screening of species-specific antibiotics **62**
Lucia Granieri, Oliver J. Miller, Andrew D. Griffiths and Christoph A. Merten

Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible *Acinetobacter* spp. **69**
M. Casal, F. Rodríguez, B. Johnson, E. Garduno, F. Tubau, R. Ortiz de Lejarazu, A. Tenorio, M. J. Giménez, R. Bartolomé, C. Garcia-Rey, L. Aguilar and N. García-Escribano

	Comparative <i>in vitro</i> activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against <i>Nocardia brasiliensis</i> , <i>Nocardia asteroides</i> and unusual <i>Nocardia</i> species <i>Chih-Cheng Lai, Che-Kim Tan, Sheng Hsiang Lin, Chun-Hsing Liao, Chien-Hong Chou, Hsiao-Leng Hsu, Yu-Tsung Huang and Po-Ren Hsueh</i>	73
	<i>In vitro</i> activity of isavuconazole against <i>Trichosporon</i> , <i>Rhodotorula</i> , <i>Geotrichum</i> , <i>Saccharomyces</i> and <i>Pichia</i> species <i>George R. Thompson III, Nathan P. Wiederhold, Deanna A. Sutton, Annette Fothergill and Thomas F. Patterson</i>	79
	Activity of physalins purified from <i>Physalis angulata</i> in <i>in vitro</i> and <i>in vivo</i> models of cutaneous leishmaniasis <i>Elisalva T. Guimarães, Milena S. Lima, Luana A. Santos, Ivone M. Ribeiro, Therezinha B. C. Tomassini, Ricardo Ribeiro dos Santos, Washington L. C. dos Santos and Milena B. P. Soares</i>	84
	Antimicrobial and antibiofilm efficacy of triclosan and DispersinB [®] combination <i>Rabih O. Darouiche, Mohammad D. Mansouri, Purushottam V. Gawande and Srinivasa Madhyastha</i>	88
	Lysostaphin eradicates established <i>Staphylococcus aureus</i> biofilms in jugular vein catheterized mice <i>John F. Kokai-Kun, Tanya Chanturiya and James J. Mond</i>	94
	Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation <i>Pavel Gershkovich, Ellen K. Wasan, Molly Lin, Olena Sivak, Carlos G. Leon, John G. Clement and Kishor M. Wasan</i>	101
av	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice <i>Massimiliano Fabbiani, Simona Di Giambenedetto, Laura Bracciale, Alessandra Bacarelli, Enzo Ragazzoni, Roberto Cauda, Pierluigi Navarra and Andrea De Luca</i>	109
av	Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naïve HIV-1-infected patients: the 2IP ANRS 127 study <i>Roland Landman, Catherine Capitant, Diane Descamps, Corine Chazallon, Gilles Peytavin, Christine Katlama, Gilles Pialoux, Michelle Bentata, Françoise Brun-Vézinet, Jean-Pierre Aboulker and Patrick Yéni on behalf of the ANRS 127 study group</i>	118
av	A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients <i>Pierre-Marie Girard, André Cabié, Christian Michelet, Renaud Verdon, Christine Katlama, Patrick Mercié, Laurence Morand-Joubert, Pascal Pétour, Françoise Monchecourt, Geneviève Chêne and Aldo Trylesinski on behalf of the COOL Study Team</i>	126
av	High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996–2007: the French ANRS CO06 PRIMO Cohort Study <i>Pierre Frange, Julie Galimand, Cécile Goujard, Christiane Deveau, Jade Ghosn, Christine Rouzioux, Laurence Meyer and Marie-Laure Chaix</i>	135
	Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution <i>Jason A. Roberts, Carl M. J. Kirkpatrick, Michael S. Roberts, Thomas A. Robertson, Andrew J. Dalley and Jeffrey Lipman</i>	142
	Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection <i>Abhijit Chakraborty, Sandip Roy, Juergen Loeffler and Ricardo L. Chaves</i>	151
	C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia—influence of antibiotic pre-treatment: results from the German competence network CAPNETZ <i>Stefan Krüger, Santiago Ewig, Jan Kunde, Alexa Hanschmann, Reinhard Marre, Norbert Suttorp and Tobias Welte on behalf of the CAPNETZ study group</i>	159

<i>Escherichia coli</i> phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark <i>Annette S. Bukh, Henrik C. Schønheyder, Jeppe M. G. Emmersen, Mette Søgaard, Søren Bastholm and Peter Roslev</i>	163
Antimicrobial resistance trends of <i>Escherichia coli</i> bloodstream isolates: a population-based study, 1998–2007 <i>Majdi N. Al-Hasan, Brian D. Lahr, Jeanette E. Eckel-Passow and Larry M. Baddour</i>	169
Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? <i>Vidya Mave, Julia Garcia-Diaz, Tareq Islam and Rodrigo Hasbun</i>	175
Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme <i>Elsbeth Lamont, R. Andrew Seaton, Merran Macpherson, Lindsay Semple, Emma Bell and Alison H. Thomson</i>	181
Outcomes of early switching from intravenous to oral antibiotics on medical wards <i>Dominik Mertz, Michael Koller, Patricia Haller, Markus L. Lampert, Herbert Plagge, Balthasar Hug, Gian Koch, Manuel Battegay, Ursula Flückiger and Stefano Bassetti</i>	188
European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe <i>Samuel Coenen, Arno Muller, Niels Adriaenssens, Vanessa Vanckerkhoven, Erik Hendrickx and Herman Goossens on behalf of the ESAC Project Group</i>	200
<hr/>	
Research letters	
A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of <i>Staphylococcus epidermidis</i> <i>Apostolos Liakopoulos, Charalambos Neocleous, Dimitra Klapsa, Maria Kanellopoulou, Iris Spiliopoulou, Kostas D. Mathiopoulos, Evangelos Papafrangas and Efi Petinaki</i>	206
Characterization of genetic determinants of extended-spectrum cephalosporinases (ESCs) in <i>Escherichia coli</i> isolates from Danish and imported poultry meat <i>Rikke D. Berghenoltz, Mikael S. Jørgensen, Lars H. Hansen, Lars B. Jensen and Henrik Hasman</i>	207
ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia <i>Ian Morrissey, Don Biek and Regina Janes</i>	209
Boropinic acid, a novel inhibitor of <i>Helicobacter pylori</i> stomach colonization <i>Eliette Touati, Valérie Michel, Marta Correia, Luigi Menghini, Salvatore Genovese, Massimo Curini and Francesco Epifano</i>	210
<hr/>	
Letters to the Editor	
Comment on: Redefining extended-spectrum β -lactamases: balancing science and clinical need <i>Karen Bush, George A. Jacoby, Gianfranco Amicosante, Robert A. Bonomo, Patricia Bradford, Giuseppe Cornaglia, Javier Garau, Helen Giamarellou, Vincent Jarlier, Luis Martinez-Martinez, Vivi Miriagou, Timothy Palzkill, Alvaro Pascual, Jesus Rodriguez-Baño, Gian Maria Rossolini, Wladimir Sougakoff and Alkiviadis Vatopoulos</i>	212
Redefining extended-spectrum β -lactamases: balancing science and clinical need—authors' response <i>Christian G. Giske, Arnfinn S. Sundsfjord, Gunnar Kahlmeter, Neil Woodford, Patrice Nordmann, David L. Paterson, Rafael Cantón and Timothy R. Walsh</i>	213
Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild–moderate liver impairment resulting from HCV-related cirrhosis <i>Massimiliano Lanzafame, Emanuela Lattuada and Fabiana Corsini</i>	215
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild–moderate liver impairment resulting from HCV-related cirrhosis—authors' response <i>Francesca Gatti, Massimo Puoti, Paola Nasta, Saverio G. Parisi and Giampiero Carosi</i>	216